Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
52
MRES Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
22.47%
Day range:
$0.0038 - $0.0070
52-week range:
$0.0016 - $0.0280
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
240.23x
P/B ratio:
21.74x
Volume:
142.1K
Avg. volume:
1.6M
1-year change:
-67.91%
Market cap:
$12M
Revenue:
$49.5K
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MRES
Institute of BioMedical Research Corp.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MRES
Institute of BioMedical Research Corp.
|
$0.0050 | -- | $12M | -- | $0.00 | 0% | 240.23x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$19.16 | $0.85 | $2.4B | 32.19x | $0.80 | 0% | 37.23x |
|
NNVC
NanoViricides, Inc.
|
$1.12 | $6.50 | $20.2M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $683.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MRES
Institute of BioMedical Research Corp.
|
-- | 0.739 | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.780 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MRES
Institute of BioMedical Research Corp.
|
-- | -- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Institute of BioMedical Research Corp. vs. Competitors
-
Which has Higher Returns MRES or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Institute of BioMedical Research Corp.'s net margin of -255.85%. Institute of BioMedical Research Corp.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital MRESInstitute of BioMedical Research Corp.-- -- -- NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About MRES or NBY?
Institute of BioMedical Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -95.56%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than Institute of BioMedical Research Corp., analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than Institute of BioMedical Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings MRESInstitute of BioMedical Research Corp.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is MRES or NBY More Risky?
Institute of BioMedical Research Corp. has a beta of -0.452, which suggesting that the stock is 145.248% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock MRES or NBY?
Institute of BioMedical Research Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Institute of BioMedical Research Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRES or NBY?
Institute of BioMedical Research Corp. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Institute of BioMedical Research Corp.'s net income of -- is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Institute of BioMedical Research Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Institute of BioMedical Research Corp. is 240.23x versus 37.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRESInstitute of BioMedical Research Corp.240.23x -- -- -- NBYNovaBay Pharmaceuticals, Inc.37.23x 32.19x $521K -$1.3M
-
Which has Higher Returns MRES or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Institute of BioMedical Research Corp.'s net margin of --. Institute of BioMedical Research Corp.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital MRESInstitute of BioMedical Research Corp.-- -- -- NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About MRES or NNVC?
Institute of BioMedical Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 480.36%. Given that NanoViricides, Inc. has higher upside potential than Institute of BioMedical Research Corp., analysts believe NanoViricides, Inc. is more attractive than Institute of BioMedical Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings MRESInstitute of BioMedical Research Corp.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is MRES or NNVC More Risky?
Institute of BioMedical Research Corp. has a beta of -0.452, which suggesting that the stock is 145.248% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.439%.
-
Which is a Better Dividend Stock MRES or NNVC?
Institute of BioMedical Research Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Institute of BioMedical Research Corp. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRES or NNVC?
Institute of BioMedical Research Corp. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Institute of BioMedical Research Corp.'s net income of -- is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Institute of BioMedical Research Corp.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Institute of BioMedical Research Corp. is 240.23x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRESInstitute of BioMedical Research Corp.240.23x -- -- -- NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns MRES or OGEN?
Oragenics, Inc. has a net margin of -- compared to Institute of BioMedical Research Corp.'s net margin of --. Institute of BioMedical Research Corp.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital MRESInstitute of BioMedical Research Corp.-- -- -- OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About MRES or OGEN?
Institute of BioMedical Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.65%. Given that Oragenics, Inc. has higher upside potential than Institute of BioMedical Research Corp., analysts believe Oragenics, Inc. is more attractive than Institute of BioMedical Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings MRESInstitute of BioMedical Research Corp.0 0 0 OGENOragenics, Inc.1 0 0 -
Is MRES or OGEN More Risky?
Institute of BioMedical Research Corp. has a beta of -0.452, which suggesting that the stock is 145.248% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock MRES or OGEN?
Institute of BioMedical Research Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Institute of BioMedical Research Corp. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRES or OGEN?
Institute of BioMedical Research Corp. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Institute of BioMedical Research Corp.'s net income of -- is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Institute of BioMedical Research Corp.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Institute of BioMedical Research Corp. is 240.23x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRESInstitute of BioMedical Research Corp.240.23x -- -- -- OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns MRES or PTN?
Palatin Technologies has a net margin of -- compared to Institute of BioMedical Research Corp.'s net margin of --. Institute of BioMedical Research Corp.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MRESInstitute of BioMedical Research Corp.-- -- -- PTNPalatin Technologies-- -- -- -
What do Analysts Say About MRES or PTN?
Institute of BioMedical Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Institute of BioMedical Research Corp., analysts believe Palatin Technologies is more attractive than Institute of BioMedical Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings MRESInstitute of BioMedical Research Corp.0 0 0 PTNPalatin Technologies0 0 0 -
Is MRES or PTN More Risky?
Institute of BioMedical Research Corp. has a beta of -0.452, which suggesting that the stock is 145.248% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock MRES or PTN?
Institute of BioMedical Research Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Institute of BioMedical Research Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRES or PTN?
Institute of BioMedical Research Corp. quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. Institute of BioMedical Research Corp.'s net income of -- is lower than Palatin Technologies's net income of --. Notably, Institute of BioMedical Research Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Institute of BioMedical Research Corp. is 240.23x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRESInstitute of BioMedical Research Corp.240.23x -- -- -- PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns MRES or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Institute of BioMedical Research Corp.'s net margin of --. Institute of BioMedical Research Corp.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital MRESInstitute of BioMedical Research Corp.-- -- -- TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About MRES or TOVX?
Institute of BioMedical Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3158.85%. Given that Theriva Biologics, Inc. has higher upside potential than Institute of BioMedical Research Corp., analysts believe Theriva Biologics, Inc. is more attractive than Institute of BioMedical Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings MRESInstitute of BioMedical Research Corp.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is MRES or TOVX More Risky?
Institute of BioMedical Research Corp. has a beta of -0.452, which suggesting that the stock is 145.248% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock MRES or TOVX?
Institute of BioMedical Research Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Institute of BioMedical Research Corp. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRES or TOVX?
Institute of BioMedical Research Corp. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Institute of BioMedical Research Corp.'s net income of -- is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Institute of BioMedical Research Corp.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Institute of BioMedical Research Corp. is 240.23x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRESInstitute of BioMedical Research Corp.240.23x -- -- -- TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
